<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90553">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694953</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI5453</org_study_id>
    <secondary_id>1U54NS078059</secondary_id>
    <nct_id>NCT01694953</nct_id>
  </id_info>
  <brief_title>The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)</brief_title>
  <acronym>NAHIM</acronym>
  <official_title>The Rare Disease Clinical Research Network Natural History Study of MNGIE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center natural history study of MNGIE (Mitochondrial NeurogastroIntestinal
      Encephalopathy).   Patients will be followed over time to assess clinical symptoms.  The
      investigators hope to learn more about the disease of MNGIE as well as develop useful
      measures of disease status  for use in future clinical trials.

      Additional clinical centers will be listed as they become available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will examine a total of 20 patients at six month intervals for up to five
      years.   The investigators will evaluate gastrointestinal function, lean body mass,
      neuropathy, neuropsychological capability, quality of life, nutrition, motor function and
      biochemical parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Timed Water Swallow</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The timed water swallow test evaluates the time it takes to swallow a small cup of water</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of Neuropathy</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A general neurological exam will be performed to assess the degree of neuropathy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Score on Mini Mental State Exam</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A short assessment of cognitive function  will be performed.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)</condition>
  <arm_group>
    <arm_group_label>Patients with MNGIE</arm_group_label>
    <description>Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female, At least 5 years of age, with Thymidine Phosphorylase defect
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Thymidine Phosphorylase (TP) defect:

               1. homozygous or

               2. compound heterozygous mutations in the TYMP gene, and/or

               3. TP enzyme activity of &lt;20% of normal.

          2. Increased plasma Thd &gt; 3 micromole/L

          3. Increased plasma dUrd &gt; 7.5 micromole/L

          4. Age requirement of at least 5 years of age.

        Exclusion Criteria:

          1. Participation in an interventional (study medication or other experimental
             intervention) study (within 1 month of participation in this study).

          2. Unable to travel to site for research visits.

          3. Unwillingness to sign informed consent form.

          4. Substance abuser
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michio Hirano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johnston Grier, BS</last_name>
    <phone>12123423671</phone>
    <email>NAMDC@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kris Engelstad, MS</last_name>
    <phone>12123056834</phone>
    <email>NAMDC@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Engelstad, MS</last_name>
      <phone>212-305-6834</phone>
      <email>ke4@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Michio Hirano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Martí R, López LC, Hirano M. Assessment of thymidine phosphorylase function: measurement of plasma thymidine (and deoxyuridine) and thymidine phosphorylase activity. Methods Mol Biol. 2012;837:121-33. doi: 10.1007/978-1-61779-504-6_8.</citation>
    <PMID>22215544</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michio Hirano</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>MNGIE</keyword>
  <keyword>Mitochondrial</keyword>
  <keyword>Mitochondrial Neurogastrointestinal encephalopathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
